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ABSTRACT
Introduction: Being born with low birth weight (less than 2.500 gr) is considered a public health
problem, with an overall world rate of about 14%. Low birth weight may result from a premature birth
(< 37 weeks of gestation), from several causes of intra-uterine growth restriction or from a combination
of both.
Areas covered: We described how, if weight and/or length at birth are not adequate for gestational
age, the newborn is considered ‘small for gestational age’ and may present several growth, hormonal
and developmental peculiarities, possibly due to the growth restriction developed during pregnancy.
Expert commentary: We provide a description of the possible mid-term consequences of being born
small for gestational age and how to follow and provide care for these babies from a multidisciplinary
point of view.
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1. Introduction: small for gestational age, former
definitions and new frontiers
The prevalence of low birth weight (LBW) (<2500 g) newborns
raises a public health problem, as it contributes to a variety of
short- and long-term adverse effects; including increased mor-
bidity and perinatal mortality, neurodevelopmental disorders,
poor growth, and metabolic disorders during adult life.
The World’s Children 2003 Report [1] described the overall
prevalence of LBW as 14%, with varying rates depending on the
region: the highest prevalence was found in South Asia (26%),
while in Europe and in industrialized countries, it is between 7%
and 9%. In 2010, the estimated prevalence of small for gesta-
tional age (SGA) births in 138 low-income and middle-income
countries was highly variable; the highest prevalence was
recorded in south Asia (44.5%), followed by sub-Saharan Africa
(25.5%) and southeast Asia (24.3%). The greatest numbers of
term-SGA infants were born in south Asia (16.2 million) and
sub-Saharan Africa (7.5 million). A major challenge in estimating
the global burden of babies born SGA is the selection of a
common reference population and, in particular, limitations of
available fetal growth references [2].
LBW may result from a condition of intrauterine growth
retardation (IUGR-intrauterine growth restriction), of preterm
delivery or a combination of both. SGA refers to a newborn
infant whose weight and/or length at birth is at least 2
Standard Deviations (SD) below the mean for the infant’s
gestational age. According to this definition, it is considered
as SGA when a neonate has a LBW but normal birth length
(BL) or a short in length one with normal BW. Although in
many countries there is lack of data on the proper incidence of
children born SGA, the worldwide estimated range is from 2%
to over 20%, depending also on the definition used [3].
During the past decades, several different definitions have
been used to classify SGA newborns, setting the cutoff at less
than the 10th centile, as for the World Health Organization
(WHO), or less than the 3rd centile. In 2007, the Consensus
Statement of the International Societies of Pediatric
Endocrinology and the Growth Hormone Research Society
recommended considering SGA newborn with weight and/or
length below −2 SD or 3rd percentile, as this definition allows
to identify the majority of the individuals at risk of short
stature in adulthood and may require appropriate auxological
follow-up during childhood and later adolescence [4].
Generally, SGA newborn infants may be classified in two
different categories: symmetrical (proportional; 30%), where
weight, length, and head circumference are all reduced; and
asymmetrical (70%), where BW is reduced, but linear growth
and head circumference are generally preserved. In either
group, measurement of head circumference is also indicated
as a measure of brain development. Babies with decreased
head circumference may experience neuropsychological pro-
blems and lower IQ scores during later development [5–7].
These two different conditions are usually linked to the
timing of the intrauterine growth restriction (IUGR) onset.
The term IUGR has been and is sometimes still used as a
synonym of SGA, but it represents a different clinical condition
referring to fetuses that have a deviation of intrauterine
growth curve in at least in two consecutive assessments by
prenatal ultrasound but that are not necessarily SGA. In fact,
while the term SGA has statistical roots including both those
who have failed in achieving their growth potential, and those
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who are constitutionally small but healthy, the term IUGR
refers to an anthropometric longitudinal evaluation through
prenatal serial ultrasounds, and defines fetuses with a failure
to achieve their growth potentiality due to prenatal patholo-
gical factors. According to these definitions, not each SGA
newborn is IUGR and, vice versa, not every IUGR newborn
will be SGA [8].
The main causes of IUGR are summarized in Table 1. Apart
from infections, that may be considered both maternal and
fetal causes and may occur at any time during pregnancy, fetal
causes (genetic abnormalities, chromosomal, congenital
anomalies) appear as precocious signs of IUGR, leading to
reductions of all body sizes (weight, length, and head circum-
ference) of the fetus and newborn (proportionate IUGR new-
borns, ‘symmetrical’) and most of the times reduced growth of
postnatal recovery (catch-up growth). Placental causes may
influence the last stages of pregnancy, inducing more fre-
quently a reduction of the BW, with normal or slightly reduced
head circumference and length (disproportionate IUGR infants,
‘asymmetrical’) and usually a good catch-up growth [9,10].
These underline the important diagnostic role played by
the biometric prenatal evaluation performed by ultrasounds,
which allows both transversal and longitudinal measurements
during pregnancy. Moreover, the use of ultrasound with
Doppler also allows to identify abnormalities of fetal-placental
and of the utero-placental circulations. Nevertheless, it should
be taken into account that it is difficult to estimate gestational
age through ultrasonographic evaluation due to the smaller
size of the IUGR fetus. The identification of SGA infants and/or
IUGR is important, seen their increased morbidity and mortal-
ity during the neonatal period and later in life (Table 2).
Small size at birth or in infancy is associated with increased
morbidity and mortality from cardiovascular and metabolic
diseases in adulthood (coronary artery disease, hypertension,
stroke, insulin resistance, glucose intolerance, diabetes melli-
tus). These observations have introduced the concept of
‘intrauterine programming,’ where adult diseases are initiated
by adverse environmental conditions at critical periods of
development, in particular during fetal life.
Most of the children born SGA recover their growth within
the first two years of age, although in few babies it can take
up to 4 years to attain a height within the normal range. It is
considered that about 8–15% of SGA, especially the symme-
trical, fail to show catch-up growth, resulting in short adult
stature in most of the cases [11,12]. Moreover, SGA children
may have low lean mass and increased central adiposity asso-
ciated to a higher risk long-term morbidity related to insulin
resistance (IR) and metabolic syndrome (MetS) [13].
Thanks to the advances in perinatology and neonatology
over the last decades, survival rates of very low birth weight
(BW <1.500 gr) (VLBW) and extremely low birth weight (BW
<1000 gr) (ELBV) premature infants has dramatically increased
[14]. Of the 135 million live births worldwide in 2010, WHO
estimates that 14.9million babies were born prematurely,
representing an increasing burden with a preterm birth rate
of 11.1% [15]. Preterm birth can be also subdivided on the
basis of gestational age (GA), as extremely preterm (EPT)
occurring at less than 28 weeks of GA, very preterm (VPT)
from 28 but less than 32 weeks, moderate preterm (MPT)
occurring from 32 and 33 + 6 and late preterm (LPT) from 34
to 36 + 6 weeks of gestation [16]. The use of birth weight as a
selection criterion has the disadvantage to include, in the
same study group, more mature children born SGA and pre-
term infants born appropriate for GA (AGA), that may present
slight differences in terms of clinical outcomes [17]. Moreover,
in a period that is usually characterized by rapid intrauterine
growth, the premature birth leads the neonate to survive in an
extra-uterine environment, shifting energy expenditure from
growth-promoting actions to survival strategies, often result-
ing in postnatal growth restriction also named extra-uterine
growth restriction (EUGR). EUGR is considered as growth
values ≤10th percentile of intrauterine growth expectation,
Table 1. Main causes of intra-uterine growth restriction.
Maternal Maternal age (<16 years; >35 years)Unfavorable socioeconomic
conditions
Parity
Malnutrition
Substance of abuse (smoking, alcohol, drugs)
Hypertension, preeclampsia
Chronic diseases: diabetes mellitus, endocrine disorders, collagen
diseases, kidney disease, cardiovascular disease, anemia.
Tumors
Malformations
Uterine malformations
Infections (particularly complex TORCH)
Placental Anatomical abnormalities
Insertion anomalies (placenta previa, occult detachment)
Anomalies funiculars (chronic compression, thrombosis of the
umbilical vessels, insertion velamentosa)
Insufficient utero-placental perfusion
Fetal Chromosomal abnormalities
Genetic diseases
Congenital metabolic diseases
Infections (particularly complex TORCH)
Table 2. Perinatal and long-term complications of the SGA/IUGR newborn.
Perinatal complications in term
and preterm newborn SGA/
IUGR
Increased perinatal mortality (chronic
hypoxia, perinatal asphyxia, congenital
anomalies)
Perinatal asphyxia
Meconium aspiration syndrome
hypothermia
Persistent pulmonary hypertension
pulmonary hemorrhage
Hypoglycemia
Hyperglycemia polycythemia/
hyperviscosity
Necrotizing enterocolitis (NEC)
Thrombocytopenia
Neutropenia
Outcomes and long-term
consequences
Increased number of days of
hospitalization at birth
Increased frequency of readmission to
the hospital
Reduced catch-up growth (SGA
symmetrical)
Minor neurological disorders
Increased incidence of attention deficit
hyperactivity disorder (ADHD)
Greatest risk of severe neurological
impairment in preterm infants
Endocrine and metabolic disorders
(insulin resistance/hyperinsulinemia,
dyslipidemia, obesity, diabetes type II)
Hypertension
Cardiovascular diseases
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based on estimated postmenstrual age in premature (23–
34 weeks’ estimated gestational age) neonates at the time
they are discharged from the hospital [18]. In a large study
from 2008, the prevalence of EUGR at 37–42 weeks of GA in
premature infants was inversely proportional to the GA at
birth, achieving peaks of 90% for neonates born at
23–26 weeks [19]. Both SGA and AGA neonates may develop
an extra-uterine growth restriction, according to the timing of
birth and to the clinical complications. Moreover, the timing of
extra-uterine growth restriction of a preterm AGA may occur
at the same time as the IUGR of the full-term baby SGA/IUGR.
It would therefore be important to evaluate whether these
two groups of infants may have a similar metabolic and aux-
ological outcome. Accordingly EUGR children who do not
show postnatal catch-up growth in early childhood may be
considered as potentially eligible for GH therapy [20].
The use of appropriate anthropometric charts is mandatory
although modalities of growth change according to intra- and
extra-uterine growth. Optimum growth of preterm infants is
considered to be equivalent to intrauterine rates since a super-
ior growth standard has not been defined [21].
Achieving term age for a preterm infant (from 37th to 40th
weeks of corrected age), generally means increasing weight and
length gain, while in-utero growth trend decreases during the
very last weeks of gestation. In fact, the PreM Growth Study
revealed that although the pattern of preterm infant growth
was generally consistent with intrauterine growth, the biggest
deviation in weight gain velocity between the preterm infants
and the fetus and infant was just before term, between 37 and
40 weeks. Intra uterine growth charts deriving from fetal mea-
surements obtained by ultrasonography, reflected the expected
growth for each gestational age without the effects of prema-
turity. Their disadvantage is the sensitivity of ultrasonography
to assess fetal weight, especially during the first weeks of
gestation [22,23]. In 2003, Fenton put together data of three
different populations and developed an intrauterine growth
chart starting at 22 weeks of gestation with a scale of weight
every 100 g. The CDC-2000 growth data between 40th and 50th
weeks after conception were added resulting in a fetal-neonatal
growth chart, which facilitates the adjustment of growth to
prematurity, recommended up to 3 years of age [24]. A new
version was released in 2013 with data from six countries. It is
now a gender-specific growth chart from 22-week gestation
until 10 weeks after term and aligns with the WHO-2006 growth
charts allowing a longer period of growth follow-up [22].
However, these growth charts are growth references and are
not a growth standard, due to the fact that the population
studied was not selected to be healthy. International data on
the estimated fetal weight (EFW) and fetal biometry are now
available from the first results of the INTERGROWTH-21st study,
and will complete the Fetal Growth Standards to be used
worldwide. The INTERGROWTH-21 prescriptive approach is in
contrast to the descriptive approach adopted in the WHO pre-
natal growth charts. In fact, Intergrowth-21 developed a new
fetal weight estimation model using data from mothers and
pregnancies which met minimum criteria in regard to age,
height, weight, diet, preexisting medical conditions and after
excluding those who developed any antenatal complications
who may have affected fetal size. The WHO EFW included
growth related antenatal complications and made use of a
preexisting weight estimation model to construct references.
The clinical suitability of the INTERGROWTH-21 and WHO EFW
references in independent populations from different parts of
the world has not yet been assessed, and needs further studies.
It is also important to bear in mind Gardosi’s point of view, that
for epidemiological analysis as well as for prospective assess-
ment of fetal growth, individual adjustments of weight limits
(the so-called customized assessment) reduce false-positive
results and help to identify those babies who are pathologically
small. This should lead to improved screening and further
investigation (especially by Doppler analysis) of those babies
who are at risk [10,25]. Italian neonatal anthropometric charts,
the so-called INeS (Italian Neonatal Study) charts, based on data
from more than 45,000 babies, have been available since 2010.
As for the international data mentioned before, these charts do
not refer to a healthy target population: the presence of fetal or
maternal pathologies with effects on intrauterine growth was
not a criterion for exclusion. New INeS charts, adjusted for
gender and parity and based on a healthy population, are
mandatory to standardize the auxological measurements of
Italian babies and provide reliable background information for
follow-up [26,27].
2. Growth in SGA
Most children born SGA recover percentiles of weight and height
after discharge, although they reach a final adult height that is
about 1 SD lower than the target height (TH) calculated from
parents’ height [12]. The typical accretive pattern is characterized
by a period of accelerated linear growth during the first
12 months of life (catch-up growth) that fades around 2 years
of age [28]. The recovery is considered completed when they
reach their genetic potential determined by the height of the
parents. However, 10–15% of those born SGA will continue to
present short stature (height ≤−2SD) during childhood and adult
life. Severe preterm infants and those with severe degrees of
growth retardation, particularly short length at birth, are less
likely to reach a stature within the normal range, although TH
plays an important role. The genetic influence on catch-up
growth appears to start from the onset of childhood: being
born short or becoming short during the first 2 years of life is
similar in terms of risk for adult short stature [29]. The first year of
life is considered a very critical period for preterm babies due to
the long hospital staying and to all the possible severe clinical
complications they may go through (bronchopulmonary dyspla-
sia, necrotizing enterocolitis, intraventricular hemorrhage, sepsis,
meningitis). Growth in weight and length may be strongly be
influenced by these complications, delaying the achieving of the
so called full enteral feeding. Preterm who survive the hospital
discharge are shorter and lighter than full-term peers, despite the
intense catch-up growth they may have had [30]. Although
preterm born SGA may take up to four years to achieve a height
in the normal range for population, about 80% of preterm chil-
dren show growth recovery during the first 2 years of life and, at
3 years of age, approximately 80% reaches the normality for
head circumference and 70% for weight [31,32]. Long-term fol-
low-up studies on very and extremely preterm infants, as the
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English UPICURE study, showed that birth weight for GA is still
strongly associated with growth outcomes at preschool and
school age. They have found, at 6 years of age, that children
born extremely preterm were still leaner, shorter and with a
smaller head circumference than their peers, with some catch-
up growth observed from 30 months to 6 years of age [33]. The
pathophysiology of postnatal growth failure is complex: different
anomalies in the GH-IGF1 axis had been described. For this
reason, the GH-IGF1 axis has been largely studied in SGA chil-
dren. Classic growth hormone deficiency is rare in this popula-
tion, although differences in diurnal GH secretion patterns
compared to AGA controls have been described: GH peaks of
production present lower amplitude and increased frequency.
When a stimulation test is performed SGA children present lower
peaks of GH secretion, although within normal range [34,35].
Mean IGF-I and IGF-binding protein-3 levels are reduced in SGA
children by approximately 1SD, but the range of levels is wide,
indicating possible heterogeneity in the mechanisms of growth
failure from insufficient IGF-I generation to IGF-I insensitivity [36].
To the best of our knowledge, SGA populations involved in these
studies are not divided into many different categories, according
to the reason of intra uterine restriction. In fact, children with
genetic or anatomical anomalies are excluded, and that most
part of the studies are considering SGA newborns due to pla-
cental- and/or infection-mediated etiology of restricted fetal
growth.
In infants born prematurely, the period equivalent to the
third trimester of gestation occurs extra-utero, with higher risk
of alterations of the GH and insulin-like growth factor system,
although related data are still controversial [37]. Recently,
medical attention regarding SGA children has also been
focused on ghrelin levels in SGA children, a peptide modulat-
ing lipid and carbohydrate metabolism and stimulating GH
secretion. It was found that ghrelin concentration is higher
in SGA than in AGA newborns, and particularly in SGA children
presenting with normal pre-pubertal height, speculating that
this may be the adaptive mechanism to stimulate IGF1 pro-
duction and achieve normal growth in SGA children. Higher
ghrelin levels may also increase the risk of long-term morbid-
ity, related to insulin resistance (IR), diabetes mellitus type 2
(DM2) and cardiovascular diseases in adulthood, typical of SGA
children and young adults [38]. We recommend, in children
born SGA, measurements of weight, length and head circum-
ference every 3 months during the first year and every
6 months during the second year of life. A child who does
not show a catch-up growth during the first 6 months of age
should receive careful auxological and endocrine monitoring
and assessment of GH-IGF1 axis may be required if growth
velocity is persistently reduced.
3. Metabolic characteristics in SGA
As mentioned above, other than the risk of adult short stature,
being born SGA is linked to higher risk of developing Mets (IR,
hypertension, and dyslipidemia), and consequently of cardio-
vascular diseases. IR may be present as early as 1 year of age,
and in pre-pubertal age, and it is evident in those with rapid
weight gain, probably due to the lower insulin-mediated glu-
cose uptake and insulin sensitivity [39]. The proposed
hypothesis to explain the association between LBW and meta-
bolic risk later in life is linked to Barker’s ‘fetal origin hypoth-
esis:’ fetal adaptation to malnutrition in utero may lead to
permanent genetic changes resulting in adult morbidities, as
the insulin resistance and the reprogramming of the pituitary-
adrenal axis results in exposure to higher doses of glucocorti-
coids [40,41]. LBW also seems to be associated with the devel-
opment of hypertension and cardiovascular diseases in
adulthood. A recent case–control study compared AGA new-
borns and children diagnosed in utero as SGA after 34 weeks
of gestation and subdivided into SGA and IUGR categories,
according to the absence or presence of weight centile less
than 3 or abnormal cerebroplacental Doppler, respectively.
Postnatal cardiovascular outcome was evaluated at 3–6 years
of age by echocardiography, blood pressure, and carotid ultra-
sound finding that both SGA and IUGR presented more glob-
ular hearts during childhood, reduced longitudinal motion,
and impaired relaxation with an increase in radial function.
Both groups showed increased blood pressure and carotid
intima-media thickness. There was a linear tendency to
worse cardiovascular results in IUGR compared with SGA
[42]. In general, during childhood, the prevalence of cardio-
vascular risk factors is low and the routine evaluation of
metabolic parameters is not justified for all the SGA born
children. Instead, it should be managed following the pediatric
guidelines for general population, emphasizing risk increase in
adulthood. Regarding body composition, SGA infants usually
show low lean body mass and increased central adiposity.
Rapid weight gain during childhood is associated with an
increased incidence of obesity in adulthood [43,44]. For pre-
term infants, body composition at term equivalent age is
different than that of infants born at term. In fact, preterm
infants have less lean tissue but similar fat mass [45]. This
seems to change during childhood and children born prema-
turely and full term seem to have similar body composition at
preschool age, and the previous differences in terms of body
composition at term age were not found at pre-school age in
a cohort of 71 children: 21 preterm and 50 term infants [46].
4. Puberty in SGA
Although puberty begins at normal age, preterm children
usually present earlier onset of pubertal development, faster
progression of puberty and earlier menarche compared to full-
term and AGA children. Age of menarche seems also to be
related to lower GA. Brandt et al. described a significant dif-
ference in age at menarche among preterm SGA girls without
catch-up growth and girls born full term and with preterm
girls born SGA with postnatal catch-up growth. Height velocity
peak is achieved at an earlier pubertal stage and is maintained
for a shorter period, increasing the risk of short adult stature.
Small bone age delay at the onset of puberty and more rapid
bone maturation during puberty has been reported, similar to
SGA children, leading to an early fusion of the growth plates
and reduced adult height [47,48]. The majority of studies
investigating the onset of puberty in children born at term
SGA and AGA established that, even though puberty begins at
an appropriate time (based on chronological age and actual
height) in SGA children, its onset happens earlier than in AGA
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children. SGA term children usually present precocious adre-
narche, possibly due to some of the major metabolic peculia-
rities of SGA children with high weight gain in childhood, such
as increased central adiposity, decreased insulin sensitivity,
and increased IGF-1 levels, that may stimulate androgen secre-
tion. Although there is no complete agreement, several stu-
dies show that menarche age in full term SGA female is
significantly lower than in AGA girls, however in the normal
age range. Regarding bone age and growth spurt, data are
similar to the preterm SGA ones, but more long-term follow-
up studies are needed to better understand the biological
mechanisms of pubertal development both in preterm and
full-term SGA children [49].
5. Brain development in SGA
Most of the studies correlating birth weight and neurological
outcomes are observational studies with many confounding
factors. Nevertheless, several associations between LBW and
poor outcomes are known in both in preterm and term
infants. Besides the risk of increased mortality and poor out-
comes during the first weeks after birth, SGA preterm infants
present an additional risk of impaired neurological develop-
ment in childhood and adulthood. Morsing et al. described the
effects of IUGR due to absent or reversed end-diastolic blood
flow in the umbilical artery, in very preterm infants (age range
24–29 weeks of gestation) born SGA compared to those born
AGA on cognitive outcome at 5–8 years of age. Children born
very preterm after IUGR had an increased risk for cognitive
impairment at early school age compared with children deliv-
ered very preterm for other reasons. Differences in cognitive
outcome were restricted to boys who may have been espe-
cially vulnerable to the influence of IUGR and very preterm
birth [50]. De Jesus et al. also showed, in a large cohort of
newborn infants born at <27 weeks of gestational age, that
compared with non-SGA infants, SGA had higher mortality and
were more likely to have postnatal growth failure, prolonged
mechanical ventilation, and postnatal steroid use. SGA status
was also associated with increased risk of death or neurode-
velopmental impairment, presenting with a higher prevalence
of cerebral palsy, blindness, cognitive delay, and short stature
compared to AGA peers [51]. Growth velocity during hospita-
lization in NICU also seems also to be associated with the
development of cerebral palsy and lower scores at the
Bayley Scale at 18–22 months of corrected age [52] and to
scholastic performances at eight years of age [53]. Moreover,
being born as premature SGA seems to impair cognitive func-
tions, in the areas of mathematics and logic areas, comprehen-
sion and attention, and to predispose to hyperactivity
disorders, especially when the growth restriction is linked to
placental flow alterations [54]. Full-term SGA infants, often
unrecognized as ‘at risk’ population because of birth weight
>2500 gr although lower than the 3rd centile for gestational
age and sex, may also develop long-term neurodevelopmental
problems. Several authors have found an increased incidence
of minor neurological dysfunction consisting in clumsiness
and motor incoordination, hyperactivity, deficit of attention,
speech and phonation problems. Considering the high
number of full-term SGA infants, neurological consequences
may represent a public health concern. A recent nationwide
Japanese study examined the impact of SGA birth on beha-
vioral development in a large SGA population, focusing on
full-term births. Motor and language development were
assessed by questionnaires at 2.5 years of age, and behavioral
problems relevant to social development or attention were
assessed at 5.5 years of age. SGA status had negative impacts
on neurodevelopmental outcomes in full-term children at
both ages, consistent with previous studies [55]. Recently,
the role of catch-up growth on influencing neurological devel-
opment was also proposed. Authors divided their 194 SGA
population in symmetric and asymmetric groups, showing
that the latter had better catch-up growth with larger head
circumference. No difference in neurodevelopmental screen-
ing was observed between SGA groups, but infants without
any catch-up growth were at higher risk of delayed outcome
[56]. The assessment of general movements (GMs) during the
first 20 weeks of age is a known method for early detection of
brain dysfunction and should also be considered also in low-
risk population, as SGA children [57]. GMs in 31 infants with
asymmetric intrauterine growth retardation and their appro-
priate AGA controls were examined and correlated with neu-
rodevelopmental outcome at 2 years. The incidence of normal
GMs was lower in the intrauterine growth retarded infants
than in the controls, and significant correlations were found
between GM quality and neurodevelopmental scores in the
intrauterine growth retarded group [58]. In a longitudinal
study on the qualitative aspects of GMs of intrauterine growth
retarded preterm infants (birth weight below 5th percentile),
Bos et al. showed a strong correlation between qualitative
assessment of GMs and outcome at 2 years of age, which
might help to identify infants at increased risk of neurodeve-
lopmental abnormalities [59]. How much an intrauterine hos-
tile environment influences the neurodevelopment of a
preterm baby is still unclear. More studies are needed (with
the cooperation of gynecologists, neonatologists and pediatri-
cians) to detect the link between impaired placental function-
ality, preterm birth, IUGR, and neurocognitive impairment. The
GMs assessment, considered a possible precocious marker of
neurological wellbeing, may help physicians in detecting who
is at higher risk of neurodevelopment impairment.
6. Conclusion
In addition to known SGA peculiarities during the first days
of life, such as hypoglycemia, thrombocytopenia, increased
perinatal morbidity and mortality, full-term and preterm
SGA may also contribute to several health consequences,
more severe when catch up growth is not achieved. The
increasing worldwide percentage of SGA newborns raises a
public health concern, which needs prevention measures.
All children born SGA should be placed in a multidisciplin-
ary follow up including neonatologists, pediatricians, nutri-
tionists, and endocrinologists, in order to monitor and
improve the neurodevelopment and long-term outcomes.
Table 3 summarizes the main indications for the SGA clinical
follow up.
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7. Expert commentary
Being born SGA, both at term and preterm, is one of the new
challenges of the contemporary pediatrician. In fact, this cate-
gory of children has been shown to be at higher risk of
developing cardiovascular and metabolic diseases. The so-
called ‘noncommunicable diseases’ (cardiovascular diseases,
diabetes, allergies, osteoporosis, some cancers, etc.) have
now become endemic in the western world and trying to
improve the diagnostic-therapeutic approach to the babies
who are ‘at risk’ or already have developed the disease is
probably not the right key. But why does IUGR influences
the newborn’s future? During intrauterine life, maternal nutri-
tion and placental integrity play a vital role in the so-called
‘metabolic programming:’ the different stimuli may cause per-
manent changes that persist throughout the course of life
with long-term implications for the subsequent development
of metabolic and neurodevelopmental diseases. These
responses are called ‘predictive adaptive responses’ (PARs)
and modulate, through different mechanisms including epige-
netic processes, the typical developmental plasticity. Among
the PARs we find metabolic control, distribution of adipose
tissue, types of muscle fibers, number of cardiomyocytes and
nephrons, appetite regulation, responses to stress, timing of
pubertal development, and development of central nervous
system. Together, they constitute an integrated system that
leads the ways in which the adult offspring responds to its
environment.
Although PARs should confer adaptive advantages, devel-
opmental changes made on the basis of early-life predictions
can turn out to be inappropriate: this is already detectable
during the first months of life and in early childhood, influen-
cing several clinical aspects of SGA children.
8. Five-year view
Advances in prenatal and perinatal medicine will be accom-
panied by important gains in the rate of survival of infants
born preterm and/or IUGR. So far, one in ten newborns in the
world are preterm while SGA newborn are about 14% of the
overall births. Physicians involved in the clinical care of this
category of children, from neonatologist to pediatric endocri-
nologists, will need to improve their knowledge to recognize
and care for these babies properly.
Key issues
● Being born with low birth weight (LBW) (<2500 g) is a
condition whose prevalence rises a public health problem,
contributing to a variety of short and long-term adverse
effects.
● SGA newborn presents weight and/or length below −2 SD
or 3rd percentile, and may be classified in two different
categories: symmetrical (proportional; 30%), and asymme-
trical (70%).
● The use of appropriate anthropometric charts is mandatory
although modalities of growth change according to intra-
and extra-uterine growth.
● Most children born SGA recovers percentiles of weight and
height after discharge, although they reach a final adult
height that is about 1 Standard Deviation lower than the
Target Height. About 10–15% of those born SGA will con-
tinue to present short stature (height ≤ −2SD) during child-
hood and adult life and may be eligible for growth
hormone treatment.
● Being born SGA is related to higher risk of developing
Metabolic Syndrome (Insulin resistance, hypertension, and
dyslipidemia), and consequently of cardiovascular diseases
in young age.
● Preterm children seem to achieve the complete pubertal
development earlier than term peers, worsening final
height. In SGA born at term, even though puberty begins
at an appropriate time, its onset happens earlier than AGA
children, usually presenting precocious adrenarche.
● Although further prospective studies are needed, an increased
incidence of minor neurological dysfunction seems to exist in
SGA children, both born preterm and at term.
Funding
No funding declared
Declaration of interest
The authors have no relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial conflict with
the subject matter or materials discussed in the manuscript. This includes
employment, consultancies, honoraria, stock ownership or options, expert
testimony, grants or patents received or pending, or royalties.
References
Papers of special note have been highlighted as either of interest (•) or of
considerable interest (••) to readers.
1. United Nations Children’s Fund. 2003. State of the World’s Children
Report, 2003. Available from: http://www.unicef.org/sowc03/con
tents/pdf/SOWC03-eng.pdf.
Table 3. Auxological, metabolic and neurodevelopmental follow up in SGA
children.
Follow up of SGA children
Prevention of cardiovascular risk
- Promotion of breast feeding and healthy eating behavior
- Monitoring weight gain using appropriate growth charts
- Promotion of physical activity and a normo-caloric diet, especially in those
who present early adipose rebound (from 2 to 6 years)
- Assessment of blood pressure once a year after three years of age
- Evaluation of lipid levels once every two years after two years of age for
those with a positive family history
- Dietary interventions and possible drug therapy in dyslipidemic patients
- Monitoring of the glucose tolerance in patients at risk for a positive family
history or steroid therapy/GH
Growth and puberty
- Height assessment with appropriate growth charts
- Early detection of no catch-up growth (consider GH treatment)
- Monitoring of puberty onset
Psychomotor development
- Age adequate neurodevelopmental assessment:
a) GMs assessment at term, 4–6 weeks and 10–16 weeks post-term age
b) Neurological examination at 3,6,12, and 24 months
c) Developmental Quotient at 6, 12, 24 months
- Attention to minor neurological disorders
- Early initiation of rehabilitation therapy when needed
6 L. IUGHETTI ET AL.
2. Lee AC, Katz J, Blencowe H, et al. National and regional estimates of
term and preterm babies born small for gestational age in 138 low-
income and middle-income countries in 2010. Lancet Glob Health.
2013;1:e26–36.
3. Saenger P, Czernichow P, Hughes I, et al. Small for gestational age:
short stature and beyond. Endocr Rev. 2007;28:219–251.
4. Clayton PE, Cianfarani S, Czernichow P, et al. Management of the
child born small for gestational age through to adulthood: a con-
sensus statement of the International Societies of Pediatric
Endocrinology and the Growth Hormone Research Society. J Clin
Endocrinol Metab. 2007;92(3):804–810.
•• Milestone for diagnosis and treatment of children born small
for gestational age.
5. Geva R, Eshel R, Leitner Y, et al. Neuropsychological outcome of
children with intrauterine growth restriction: a 9-year prospective
study. Pediatrics. 2006;118:91–100.
6. Brandt I, Sticker EJ, Lentze MJ. Catch-up growth of head circumfer-
ence of very low birth weight, small for gestational age preterm
infants and mental development to adulthood. J Pediatr.
2003;142:463–468.
7. Frisk V, Amsel R, Whyte HE. The importance of head growth pat-
terns in predicting the cognitive abilities and literacy skills of small-
for-gestational-age children. Dev Neuropsychol. 2002;22:565–593.
8. Lee PA, Chernausek SD, Hokken-Koelega A, et al. International
small for gestational age advisory board consensus development
conference statement: management of short children born small
for gestational age. Pediatrics. 2003;111:1253–1261.
• A masterpiece in SGA management.
9. Maulik D. Fetal growth compromise: definitions, standards, and
classification. Clin Obstet Gynecol. 2006;49(2):214–218.
10. Gardosi J. New definition of small for gestational age based on fetal
growth potential. Horm Res. 2006;65(Suppl 3):15–18.
11. Albertsson-Wikland K, Karlberg J. Natural growth in children born
small for gestational age with and without catch-up growth. Acta
Paediatr Suppl. 1994;399:64–70.
12. Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-
gestational-age infants: from birth to final height. Pediatr Res.
1995;38(5):733–739.
13. Vaag A, Jensen CB, Poulsen P, et al. Metabolic aspects of insulin
resistance in individuals born small for gestational age. Horm Res.
2006;65(Suppl 3):137–143.
14. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional,
and worldwide estimates of preterm birth rates in the year 2010
with time trends since 1990 for selected countries: a systematic
analysis and implications. Lancet. 2012;379:2162–2172.
15. Blencowe H, Cousens S, Chou D, et al. Born too soon: the global
epidemiology of 15 million preterm births. Reprod Health. 2013;10
(Suppl 1):S2.
16. Engle WA. A recommendation for the definition of ‘Late preterm’
(Near term) and the birth weight-gestational age classification
system. Semin Perinatol. 2006;30(1):2–7.
17. Smith LK, Draper ES, Field D. Long-term outcome for the tiniest or
most immature babies: survival rates. Semin Fetal Neonatal Med.
2014;19(2):72–77.
18. Clark RH, Thomas P, Peabody J. Extrauterine growth restriction
remains a serious problem in prematurely born neonates.
Pediatrics. 2003;111:986–990.
19. Sakurai M, Itabashi K, Sato Y, et al. Hibino S, Mizuno K Extrauterine
growth restriction in preterm infants of gestational age < or =32
weeks. Pediatr Int. 2008;50:70–75.
20. Pampanini V, Boiani A, De Marchis C, et al. Preterm infants with
severe extrauterine growth retardation (EUGR) are at high risk of
growth impairment during childhood. Eur J Pediatr. 2015;174
(1):33–41.
•• A very interesting focus on EUGR.
21. Boguszewski MC, Cardoso-Demartini AA. MANAGEMENT OF
ENDOCRINE DISEASE: growth and growth hormone therapy in short
children born preterm. Eur J Endocrinol. 2017;176(3):R111–R122.
•• Mandatory for doctors involved in prematurity.
22. Fenton TR, Kim JH. A systematic review and meta-analysis to revise
the Fenton growth chart for preterm infants. BMC Pediatr.
2013;13:59.
• Interesting meta-analysis for growth charts.
23. Pereira-da-Silva L, Virella D. Is intrauterine growth appropriate to
monitor postnatal growth of preterm neonates? BMC Pediatrics.
2014;14:14.
24. Fenton TR. A new growth chart for preterm babies: babson and
Benda’s chart updated with recent data and a new format. BMC
Pediatr. 2003;3:13.
25. Cheng YKY, Lu J, Leung TY, et al. Prospective Assessment of the
INTERGROWTH-21 and WHO estimated fetal weight reference
curve. Ultrasound Obstet Gynecol. 2017. DOI:10.1002/uog.17514
26. Stirnemann J, Villar J, Salomon LJ, et al. International estimated
fetal weight standards of the INTERGROWTH-21st Project.
Ultrasound Obstet Gynecol. 2016. DOI:10.1002/uog.17347.
27. Bertino E, Spada E, Occhi L, et al. Neonatal anthropometric charts:
the Italian neonatal study compared with other European studies.
Jpgn. 2010;51:353–361.
• Important for Italian Neonatologists and Pediatric
Endocrinologists.
28. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, et al. Children
born small for gestational age: do they catch up? Pediatr Res.
1995;38:267–271.
29. Luo ZC, Albertsson-Wikland K, Karlberg J. Length and body mass
index at birth and target height influences on patterns of postnatal
growth in children born small for gestational age. Pediatrics.
1998;102:E72.
30. Westerberg AC, Henriksen C, Ellingvag A, et al. First year growth
among very low birth weight infants. Acta Paed. 2010;99:556–562.
31. Itabashi K, Mishina J, Tada H, et al. Longitudinal follow-up of height up
to five years of age in infants born preterm small for gestational age;
comparison to full-term 77 small for gestational age infants. Early Hum
Dev. 2007;83:327–333.
32. Monset-Couchard M, De Bethmann O. Catch-up growth in 78 166
small-for- gestational age premature infants weighing less
than 1000 g at birth. Biol Neonate. 2000;78:161–167.
33. Bracewell MA, Hennessy EM, Wolke D, et al. The EPICure
study: growth and blood pressure at 6 years of age following
extremely preterm birth. Arch Dis Child Fetal Neonatal Ed. 2008;93
(2):F108–F114.
34. De Waal WJ, Hokken-Koelega AC, Stijnen T, et al. Endogenous and
stimulated GH secretion, urinary GH excretion, and plasma IGF-I
and IGF-II levels in prepubertal children with short stature after
intrauterine growth retardation. The Dutch Working Group on
Growth Hormone. Clin Endocrinol (Oxf). 1994;41:621–630.
35. Boguszewski M, Rosberg S, Spontaneous A-WK. 24- hour growth
hormone profiles in prepubertal small for gestational age children.
J Clin Endocrinol Metab. 1995;80:2599–2606.
36. Albertsson-WIkland K, Boguszewski M, Karlberg J. Children born
small for gestational age: postnatal growth and hormonal status.
Horm Res. 1998;49(Suppl 2):7–13.
37. Cutfield WS, Regan FA, Jackson WE, et al. The endocrine conse-
quences for very low birth weight premature infants. Growth Horm
IGF Res. 2004;14(Suppl A):S130–S135.
38. Stawerska R, Szałapska M, Hilczer M, et al. Ghrelin, insulin-like
growth factor I and adipocytokines concentrations in born small
for gestational age prepubertal children after the catch-up growth.
J Pediatr Endocrinol Metab. 2016;29(8):939–945.
39. Crowther NJ, Cameron N, Trusler J, et al. Association between poor
glucose tolerance and rapid post natal weight gain in seven-year
old children. Diabetologia. 1998;41:1163–1167.
40. Mericq V, Medina P, Kakarieka E, et al. Differences in expression and
activity of 11beta-hydroxysteroid dehydrogenase type 1 and 2 in
human placentas of term pregnancies according to birth weight
and gender. Eur J Endocrinol. 2009;161:419–425.
41. Seckl JR, Holmes MC. Mechanisms of disease: glucocorticoids, their
placental metabolism and fetal ‘programming’ of adult pathophy-
siology. Nat Clin Pract Endocrinol Metab. 2007;3:479–488.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM 7
42. Crispi F, Figueras F, Cruz-Lemini M, et al. Cardiovascular program-
ming in children born small for gestational age and relationship
with prenatal signs of severity. Am J Obstet Gynecol. 2012;207
(2):121.e1-9.
43. Baird J, Fisher D, Lucas P, et al. Being big or growing fast: systema-
tic review of size and growth in infancy and later obesity. BMJ.
2005;331:929.
44. Monteiro PO, Victora CG. Rapid growth in infancy and childhood and
obesity in later life: a systematic review. Obes Rev. 2005;6:143–154.
45. Johnson MJ, Wootton SA, Leaf AA, et al. Preterm birth and body
composition at term equivalent age: a systematic review and meta-
analysis. Pediatrics. 2012;130(3):e640–9.
46. Scheurer JM, Zhang L, Gray HL, et al. Body composition trajectories
from infancy to preschool in children born premature versus full-
term. J Pediatr Gastroenterol Nutr. 2017;64(6):e147-e153
47. Wehkalampi K, Hovi P, Dunkel L, et al. Advanced pubertal growth
spurt in subjects born preterm: the Helsinki study of very low birth
weight adults. J Clin Endocrinol Metab. 2011;96(2):525–533.
48. Lazar L, Pollak U, Kalter-Leibovici O, et al. Pubertal course of
persistently short children born small for gestational age (SGA)
compared with idiopathic short children born appropriate for
gestational age (AGA). Eur J Endocrinol. 2003;149(5):425–432.
49. Verkauskiene R, Petraitiene I, Albertsson Wikland K. Puberty
in children born small for gestational age. Horm Res. 2013;80:69–77.
50. Morsing E, Asard M, Ley D, et al. Cognitive function after intrauter-
ine growth restriction and very preterm birth. Pediatrics. 2011;127
(4):e874–e882.
51. De Jesus LC, Pappas A, Shankaran S, et al. Outcomes of small for
gestational age infants born at <27 weeks’ gestation. J Pediatr.
2013;163(1):55–60.
52. Ehrenkranz RA, Dusick AM, Vohr BR, et al. Growth in the neonatal
intensive care unit influences neurodevelopmental and growth
outcomes of extremely low birth weight infants. Pediatrics.
2006;117(4):1253–1261.
53. Saigal S, Stoskopf BL, Streiner DL, et al. Physical growth and
current health status of infants who were of extremely low
birth weight and controls at adolescence. Pediatrics. 2001;108
(2):407–415.
54. A-K VB, Kollmann M, Rotky-Fast C, et al. Perinatal complications
and long-term neurodevelopmental outcome of infants with
intrauterine growth restriction. Am J Obstet Gynecol.
2013;208:130.e1-6.
55. Takeuchi A, Yorifuji T, Takahashi K, et al. Neurodevelopment in full-
term small for gestational age infants: a nationwide Japanese
population-based study. Brain Dev. 2016;38(6):529–537.
56. Maciejewski E, Hamon I, Fresson J, et al. Growth and neurodeve-
lopment outcome in symmetric versus asymmetric small for gesta-
tional age term infants. J Perinatol. 2016;36(8):670–675.
57. Einspieler C, Prechtl HFR, Bos AF, et al. Prechtl’s method on the
qualitative assessment of general movements in preterm, term and
young infants. Clin Dev Med. 2004;167:1–91.
•• A milestone for understanding general movements.
58. Zuk L, Harel S, Leitner Y, et al. Neonatal general movements: an
early predictor for neurodevelopmental outcome in infants
with intrauterine growth retardation. J Child Neurol. 2004;19
(1):14–18.
59. Bos AF, Van Loon AJ, Hadders-Algra M, et al. Spontaneous motility
in preterm, small-for-gestational age infants. II. Qualitative aspects.
Early Hum Dev. 1997;50(1):131–147.
• New horizons in GMs clinical application.
8 L. IUGHETTI ET AL.
